================================================================================
CLINICAL TRIALS MATCHING REPORT
================================================================================

Patient ID: 2
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G3 NET, Ki67 48%.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Clinical Question: Weitere Therapie?
Report generated: 2025-07-08 14:37:34

Found 20 relevant clinical trials
--------------------------------------------------------------------------------

1. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
   NCT ID: NCT03375320
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Relevance Score: 1.000
   Relevance Reason: Condition match: Metastatic Digestive System Neuroendocrine Neoplasm; Condition match: Metastatic Digestive System Neuroendocrine Tumor G1; Condition match: Metastatic Lung Neuroendocrine Neoplasm; Condition match: Metastatic Lung Neuroendocrine Tumor; Condition match: Metastatic Pancreatic Neuroendocrine Neoplasm; Condition match: Metastatic Pancreatic Neuroendocrine Tumor; Condition match: Metastatic Thymus Neuroendocrine Neoplasm; Relevant intervention: cabozantinib; Eligibility match: metastatic; Eligibility match: grade 3
   Condition: Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Lung Neuroendocrine Neoplasm; Unresectable Pancreatic Neuroendocrine Neoplasm; Unresectable Thymus Neuroendocrine Neoplasm
   Intervention: Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2018-10-26
   Completion Date: 2025-11-22
   Locations: Katmai Oncology Group, Anchorage, United States; Kingman Regional Medical Center, Kingman, United States; Mayo Clinic Hospital in Arizona, Phoenix, United States
   URL: https://clinicaltrials.gov/study/NCT03375320
----------------------------------------

2. Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
   NCT ID: NCT04754425
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Relevance Score: 0.950
   Relevance Reason: Condition match: Metastatic Malignant Neoplasm in the Bone; Condition match: Metastatic Prostate Adenocarcinoma; Condition match: Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Eligibility match: metastatic
   Condition: Castration-Resistant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate Adenocarcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
   Intervention: Biopsy; Biospecimen Collection; Erdafitinib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2021-07-15
   Completion Date: 2026-06-30
   Locations: M D Anderson Cancer Center, Houston, United States
   URL: https://clinicaltrials.gov/study/NCT04754425
----------------------------------------

3. Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib
   NCT ID: NCT02713763
   Status: COMPLETED
   Phase: PHASE2
   Relevance Score: 0.700
   Relevance Reason: Condition match: Pancreatic Neuroendocrine Tumour Metastatic; Title match: metastatic; Relevant intervention: sunitinib; Eligibility match: metastatic
   Condition: Pancreatic Neuroendocrine Tumour Metastatic
   Intervention: Sunitinib
   Sponsor: Grupo Espanol de Tumores Neuroendocrinos
   Start Date: 2017-02-14
   Completion Date: 2019-10-23
   Locations: Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Valle de Hebrón, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain
   URL: https://clinicaltrials.gov/study/NCT02713763
----------------------------------------

4. Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
   NCT ID: NCT01204476
   Status: COMPLETED
   Phase: PHASE1
   Relevance Score: 0.650
   Relevance Reason: Condition match: Metastatic Digestive System Neuroendocrine Tumor G1; Relevant intervention: octreotide; Relevant intervention: everolimus; Eligibility match: metastatic
   Condition: Gastrin-Producing Neuroendocrine Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Paraganglioma; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Merkel Cell Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Regional Digestive System Neuroendocrine Tumor G1; Somatostatin-Producing Neuroendocrine Tumor; Stage III Merkel Cell Carcinoma; Stage IV Merkel Cell Carcinoma; Thyroid Gland Medullary Carcinoma
   Intervention: Cixutumumab; Everolimus; Laboratory Biomarker Analysis; Octreotide Acetate; Pharmacological Study
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2010-10
   Completion Date: 
   Locations: M D Anderson Cancer Center, Houston, United States
   URL: https://clinicaltrials.gov/study/NCT01204476
----------------------------------------

5. Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
   NCT ID: NCT05477576
   Status: RECRUITING
   Phase: PHASE3
   Relevance Score: 0.650
   Relevance Reason: Relevant intervention: octreotide; Relevant intervention: lanreotide; Relevant intervention: everolimus; Relevant intervention: sunitinib; Eligibility match: metastatic
   Condition: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET
   Intervention: RYZ101; Everolimus; Sunitinib; Octreotide; Lanreotide
   Sponsor: RayzeBio, Inc.
   Start Date: 2022-03-24
   Completion Date: 2028-07
   Locations: Research Facility, Phoenix, United States; Research Facility, Duarte, United States; Research Facility, Irvine, United States
   URL: https://clinicaltrials.gov/study/NCT05477576
----------------------------------------

6. Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
   NCT ID: NCT00093782
   Status: COMPLETED
   Phase: PHASE2
   Relevance Score: 0.550
   Relevance Reason: Condition match: Metastatic Gastrointestinal Carcinoid Tumor; Title match: metastatic; Eligibility match: metastatic
   Condition: Metastatic Gastrointestinal Carcinoid Tumor; Pulmonary Carcinoid Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma
   Intervention: temsirolimus; laboratory biomarker analysis
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2003-12
   Completion Date: 2011-04
   Locations: Princess Margaret Hospital Phase 2 Consortium, Toronto, Canada
   URL: https://clinicaltrials.gov/study/NCT00093782
----------------------------------------

7. Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
   NCT ID: NCT05040360
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.500
   Relevance Reason: Condition match: Metastatic Malignant Neoplasm in the Liver; Relevant intervention: temozolomide; Eligibility match: metastatic
   Condition: Metastatic Malignant Neoplasm in the Liver; Pancreatic Neuroendocrine Tumor; Stage I Pancreatic Neuroendocrine Tumor AJCC v8; Stage II Pancreatic Neuroendocrine Tumor AJCC v8; Stage III Pancreatic Neuroendocrine Tumor AJCC v8
   Intervention: Capecitabine; Temozolomide
   Sponsor: SWOG Cancer Research Network
   Start Date: 2022-05-05
   Completion Date: 2027-03-31
   Locations: Anchorage Associates in Radiation Medicine, Anchorage, United States; Anchorage Radiation Therapy Center, Anchorage, United States; Alaska Breast Care and Surgery LLC, Anchorage, United States
   URL: https://clinicaltrials.gov/study/NCT05040360
----------------------------------------

8. Spanish Series of Patients Treated With the Radionuclide Lutetium177
   NCT ID: NCT04949282
   Status: RECRUITING
   Phase: N/A
   Relevance Score: 0.350
   Relevance Reason: Relevant intervention: lutetium; Relevant intervention: dotatate; Eligibility match: metastatic
   Condition: Neuroendocrine Tumors; Intestinal Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Endocrine Gland Neoplasms; Digestive System Diseases; Gastrointestinal Disease; Intestinal Diseases; Pancreatic Disease; Endocrine System Diseases
   Intervention: Lutetium [177Lu] oxodotreotide/dotatate; Lutetium [177Lu] oxodotreotide/dotatate
   Sponsor: Sociedad Española de Medicina Nuclear e Imagen Molecular
   Start Date: 2021-05-10
   Completion Date: 2035-12-31
   Locations: Hospital Clínico Universitario de Santiago, Santiago De Compostela, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain
   URL: https://clinicaltrials.gov/study/NCT04949282
----------------------------------------

9. Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
   NCT ID: NCT01010126
   Status: COMPLETED
   Phase: PHASE2
   Relevance Score: 0.350
   Relevance Reason: Condition match: Metastatic Digestive System Neuroendocrine Tumor G1; Eligibility match: metastatic
   Condition: Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; Endometrial Serous Adenocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Lung Carcinoid Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Metastatic Digestive System Neuroendocrine Tumor G1; Ovarian Carcinosarcoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Polypeptide Tumor; Recurrent Adult Liver Carcinoma; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Regional Digestive System Neuroendocrine Tumor G1; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Corpus Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer; Uterine Carcinosarcoma
   Intervention: Bevacizumab; Temsirolimus
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2009-09-08
   Completion Date: 2017-03-13
   Locations: Mayo Clinic in Arizona, Scottsdale, United States; Tower Cancer Research Foundation, Beverly Hills, United States; City of Hope Comprehensive Cancer Center, Duarte, United States
   URL: https://clinicaltrials.gov/study/NCT01010126
----------------------------------------

10. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
   NCT ID: NCT00454363
   Status: COMPLETED
   Phase: PHASE2
   Relevance Score: 0.350
   Relevance Reason: Condition match: Metastatic Digestive System Neuroendocrine Tumor G1; Eligibility match: metastatic
   Condition: Gastrin-Producing Neuroendocrine Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Multiple Endocrine Neoplasia Type 1; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Pancreatic Neuroendocrine Carcinoma; Regional Digestive System Neuroendocrine Tumor G1; Somatostatin-Producing Neuroendocrine Tumor
   Intervention: Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2007-03
   Completion Date: 2014-12
   Locations: Massachusetts General Hospital Cancer Center, Boston, United States; Dana-Farber Cancer Institute, Boston, United States; M D Anderson Cancer Center, Houston, United States
   URL: https://clinicaltrials.gov/study/NCT00454363
----------------------------------------

11. Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
   NCT ID: NCT05048901
   Status: RECRUITING
   Phase: PHASE1
   Relevance Score: 0.350
   Relevance Reason: Relevant intervention: lanreotide; Relevant intervention: cabozantinib; Eligibility match: metastatic
   Condition: Neuroendocrine Tumors,Gastroenteropancreatic
   Intervention: Cabozantinib; Lanreotide
   Sponsor: National Health Research Institutes, Taiwan
   Start Date: 2021-09-17
   Completion Date: 2026-12-31
   Locations: Changhua Christian Hospital, Changhua, Taiwan; Chang Gung Medical Foundation, Kaohsiung, Taiwan; Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
   URL: https://clinicaltrials.gov/study/NCT05048901
----------------------------------------

12. An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
   NCT ID: NCT05884255
   Status: RECRUITING
   Phase: PHASE3
   Relevance Score: 0.350
   Relevance Reason: Relevant intervention: octreotide; Relevant intervention: lutetium; Eligibility match: metastatic
   Condition: Advanced Gastroenteropancreatic Neuroendocrine Tumor
   Intervention: Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide; long-acting Octreotide.
   Sponsor: Jiangsu HengRui Medicine Co., Ltd.
   Start Date: 2023-07-06
   Completion Date: 2030-10
   Locations: Tianjin University Cancer Institute and Hospital, Tianjin, China
   URL: https://clinicaltrials.gov/study/NCT05884255
----------------------------------------

13. Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer
   NCT ID: NCT04977596
   Status: COMPLETED
   Phase: N/A
   Relevance Score: 0.300
   Relevance Reason: Condition match: CT
   Condition: Neuroendocrine Tumor of Pancreas; Carcinoma, Pancreatic; CT
   Intervention: No intervention
   Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
   Start Date: 2012-01-01
   Completion Date: 2019-06-25
   Locations: Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
   URL: https://clinicaltrials.gov/study/NCT04977596
----------------------------------------

14. Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
   NCT ID: NCT02955069
   Status: COMPLETED
   Phase: PHASE2
   Relevance Score: 0.300
   Relevance Reason: Title match: metastatic; Eligibility match: metastatic; Eligibility match: grade 3
   Condition: Well-differentiated Non-functional NET of Thoracic Origin; Well-differentiated Non-functional NET of Gastrointestinal Origin; Well-differentiated Non-functional NET of Pancreatic Origin; Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
   Intervention: PDR001
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2017-02-14
   Completion Date: 2020-05-13
   Locations: City of Hope National Medical Center, Duarte, United States; Rocky Mountain Cancer Centers SC-2, Denver, United States; H Lee Moffitt Cancer Center and Research Institute, Tampa, United States
   URL: https://clinicaltrials.gov/study/NCT02955069
----------------------------------------

15. A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
   NCT ID: NCT01262235
   Status: COMPLETED
   Phase: PHASE1
   Relevance Score: 0.300
   Relevance Reason: Condition match: NET
   Condition: Cancer; Neuroendocrine Tumors; NET; Adrenocortical Carcinoma; ACC
   Intervention: TKM-080301
   Sponsor: Arbutus Biopharma Corporation
   Start Date: 2010-12
   Completion Date: 2015-08
   Locations: Scottsdale Healthcare Research Institute, Scottsdale, United States; Mayo Clinic Arizona, Scottsdale, United States; Moffitt Cancer Center, Tampa, United States
   URL: https://clinicaltrials.gov/study/NCT01262235
----------------------------------------

16. Genetics of Appendix Cancer Study
   NCT ID: NCT05734430
   Status: RECRUITING
   Phase: N/A
   Relevance Score: 0.300
   Relevance Reason: Condition match: Appendix Cancer Metastatic
   Condition: Appendix Cancer; Appendiceal Cancer; Appendiceal Neoplasms; Appendiceal Mucinous Neoplasm; Appendiceal Adenocarcinoma; Appendiceal Carcinoid Tumor; Appendiceal Neoplasm Malignant Secondary; Appendix Adenocarcinoma; Appendix Mucinous Neoplasm; Appendix Tumor; Appendix Cancer Metastatic; Appendix NET; Low-Grade Appendix Mucinous Neoplasm; High Grade Appendix Mucinous Neoplasm; High Grade Appendix Mucinous Adenocarcinoma
   Intervention: Genetic profiling; Retrospective tissue procurement
   Sponsor: Andreana Holowatyj, PhD, MSCI
   Start Date: 2022-11-11
   Completion Date: 2034-11
   Locations: Vanderbilt-Ingram Cancer Center, Nashville, United States
   URL: https://clinicaltrials.gov/study/NCT05734430
----------------------------------------

17. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
   NCT ID: NCT03452774
   Status: RECRUITING
   Phase: N/A
   Relevance Score: 0.300
   Relevance Reason: Condition match: Cancer, Metastatic
   Condition: Cancer, Metastatic; Cancer; Cancer of Pancreas; Cancer of Liver; Cancer of Stomach; Cancer Liver; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Cervix; Cancer of Colon; Cancer of Larynx; Cancer, Lung; Cancer, Breast; Cancer, Advanced; Cancer Prostate; Cancer of Neck; Cancer of Skin; Neuroendocrine Tumors; Carcinoma; Mismatch Repair Deficiency; BRCA Gene Rearrangement; Non Hodgkin Lymphoma; Leukemia; Non Small Cell Lung Cancer; Cholangiocarcinoma; Glioblastoma; Central Nervous System Tumor; Melanoma; Urothelial Carcinoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Testicular Cancer; Breast Cancer; COVID; Myelofibrosis; Myeloproliferative Neoplasm; Myeloproliferative Disorders; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Myelodysplastic Syndromes
   Intervention: Clinical Trial Matching
   Sponsor: Massive Bio, Inc.
   Start Date: 2018-01-01
   Completion Date: 2027-06
   Locations: Massive Bio, Inc, New York, United States
   URL: https://clinicaltrials.gov/study/NCT03452774
----------------------------------------

18. Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
   NCT ID: NCT04711135
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Relevance Score: 0.300
   Relevance Reason: Relevant intervention: lutetium; Relevant intervention: dotatate
   Condition: Gastroenteropancreatic Neuroendocrine Tumors; Pheochromocytoma; Paraganglioma
   Intervention: Lutetium [177Lu] oxodotreotide/dotatate
   Sponsor: Advanced Accelerator Applications
   Start Date: 2022-08-31
   Completion Date: 2034-05-07
   Locations: University of Kentucky, Lexington, United States; Cincinnati Children's Hospital, Cincinnati, United States; Children's Hospital of Philadelphia, Philadelphia, United States
   URL: https://clinicaltrials.gov/study/NCT04711135
----------------------------------------

19. Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
   NCT ID: NCT00602082
   Status: COMPLETED
   Phase: PHASE2
   Relevance Score: 0.250
   Relevance Reason: Title match: metastatic; Eligibility match: metastatic
   Condition: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor
   Intervention: capecitabine; cisplatin; streptozocin; DNA analysis; RNA analysis; protein analysis; proteomic profiling; laboratory biomarker analysis
   Sponsor: Cambridge University Hospitals NHS Foundation Trust
   Start Date: 2005-08
   Completion Date: 2009-12
   Locations: Basildon University Hospital, Basildon, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
   URL: https://clinicaltrials.gov/study/NCT00602082
----------------------------------------

20. ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
   NCT ID: NCT00339131
   Status: COMPLETED
   Phase: PHASE1
   Relevance Score: 0.250
   Relevance Reason: Title match: metastatic; Eligibility match: metastatic
   Condition: Pheochromocytoma; Paraganglioma; Carcinoid
   Intervention: Ultratrace iobenguane I 131
   Sponsor: Molecular Insight Pharmaceuticals, Inc.
   Start Date: 2006-06
   Completion Date: 2007-01
   URL: https://clinicaltrials.gov/study/NCT00339131
----------------------------------------